Abstract
In mammalian cells homologous recombination is stimulated, when the replication fork stalls at DNA breaks or unrepaired lesions. The tumor suppressor p53 downregulates homologous recombination independently of its transcriptional transactivation function and has been linked to enzymes of DNA recombination and replication. To study recombination with respect to replication, we utilized a SV40 virus based assay, to follow the synchronous events after primate cell infection. γ-ray treatment at different times after viral entry unveiled an increase of interchromosomal exchange frequencies, when the damage was introduced during DNA synthesis. Elevated recombination frequencies were fully suppressed by p53. With respect to the downregulation of spontaneous recombination, we noticed a requirement for active p53 molecules, when replication started. After a transient treatment with replication inhibitors, we observed inhibition of the drug induced recombination by p53, particularly for the elongation inhibitor aphidicolin. Consequently, we propose that p53 is a surveillance factor of homologous recombination at replication forks, when they stall as a consequence of endogenous or of exogenously introduced damage.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Akyüz N, Boehden GS, Sösse S, Rimek A, Preuss U, Scheidtmann KH, Wiesmüller L . 2002 Mol. Cell. Biol., in press
Bertrand P, Rouillard D, Boulet A, Levalois C, Soussi T, Lopez BS . 1997 Oncogene 14: 1117–1122
Braithwaite AW, Stürzbecher HW, Addison C, Palmer C, Rudge K, Jenkins JR . 1987 Nature 329: 458–460
Brush GS, Kelly TJ, Stillman B . 1995 Methods Enzymol. 262: 522–548
Cox MM, Goodman MF, Kreuzer KN, Sherratt DJ, Sandler SJ, Marians KJ . 2000 Nature 404: 37–41
Dai Y, Gold B, Vishwanatha JK, Rhode SL . 1994 Virology 205: 210–216
Dudenhöffer C, Rohaly G, Will K, Deppert W, Wiesmüller L . 1998 Mol. Cell. Biol. 18: 5332–5342
Dudenhöffer C, Kurth M, Janus F, Deppert W, Wiesmüller L . 1999 Oncogene 18: 5773–5784
Fernandez JL, Vazquez-Gundin F, Rivero MT, Genesca A, Gosalvez J, Goyanes V . 2001 Exp. Cell Res. 270: 102–109
Gersten KM, Kemp CJ . 1997 Nature Genet. 17: 378–379
Gilbert DM, Neilson A, Miyazawa H, DePamphilis ML, Burhans WC . 1995 J. Biol. Chem. 270: 9597–9606
Gottifredi V, Shieh S-Y, Taya Y, Prives C . 2001 Proc. Natl. Acad. Sci. USA 98: 1036–1041
Haber J . 1999 Trends Biol. Sci. 24: 271–275
Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R, Harris CC . 1994 Nucleic Acids Res. 22: 3551–3555
Huang P . 1998 Oncogene 17: 261–270
Ishizaki K, Ejima Y, Matsunaga T, Hara R, Sakamoto A, Ikenaga M, Ikawa Y, Aizawa S . 1994 Int. J. Cancer 58: 254–257
Janz C, Süsse S, Wiesmüller L . 2002 Oncogene 21: 2130–2140
Jimenez GS, Nister M, Stommel JM, Beeche M, Barcarse EA, Zhang XQ, O'Gorman S, Wahl GM . 2000 Nature Genet. 26: 37–43
Kalejta RF, Hamlin JL . 1997 Exp. Cell Res. 231: 173–183
Kawasaki I, Bae YS, Eki T, Kim Y, Ikeda H . 1994 Mol. Cell. Biol. 14: 4173–4182
Kaufmann WK, Wilson SJ . 1994 Mutat. Res. 314: 67–76
Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV . 1999 Science 85: 1733–1737
Kühn C, Müller F, Melle C, Nasheuer HP, Janus F, Deppert W, Grosse F . 1999 Oncogene 18: 769–774
Larner JM, Lee H, Little RD, Dijkwel PA, Schildkraut CL, Hamlin JL . 1999 Nucleic Acids Res. 27: 803–809
Levenson V, Hamlin JL . 1993 Nucleic Acids Res. 21: 3997–4004
Levine A . 1997 Cell 88: 323–331
Liang F, Han M, Romanienko PJ, Jasin M . 1998 Proc. Natl. Acad. Sci. USA 95: 5172–5177
Lin J-Y, Simmons DT . 1991 J. Virol. 65: 2066–2072
Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD . 1992 Cell 70: 923–935
Miller SD, Farmer G, Prives G . 1995 Mol. Cell. Biol. 15: 6554–6660
Saintigny Y, Lopez BS . 2002 Oncogene 21: 488–492
Saintigny Y, Delacote F, Vares G, Petitot F, Lambert S, Averbeck D, Lopez B . 2001 EMBO J. 20: 3861–3870
Saintigny Y, Rouillard D, Chaput B, Soussi T, Lopez BS . 1999 Oncogene 18: 3553–3565
Sarasin AR, Hanawalt PC . 1978 Proc. Natl. Acad. Sci. USA 75: 346–350
Scully R, Chen J, Ochs RL, Keegan K, Hoekstra M, Feunteun J, Livingston DM . 1997 Cell 90: 425–435
Stürzbecher H-W, Donzelmann B, Henning W, Knippschild U, Buchhop S . 1996 EMBO J. 15: 1992–2002
Süsse S, Janz C, Janus F, Deppert W, Wiesmüller L . 2000 Oncogene 19: 4500–4512
Thompson LH, Schild D . 2001 Mutat. Res. 477: 131–153
Tooze J (ed.) . 1980 DNA Tumor Viruses Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press
Von der Weth A, Deppert W . 1993 J. Virol. 67: 886–893
Wiesmüller L, Cammenga J, Deppert WW . 1996 J. Virol. 70: 737–744
Willers H, McCarthy EE, Wu B, Wunsch H, Tang W, Taghian DG, Xia F, Powell SN . 2000 Oncogene 19: 632–639
Zhou J, Ahn J, Wilson SH, Prives C . 2001 EMBO J. 20: 914–923
Acknowledgements
We thank Evelyn Bendrat for competent experimental assistance. This work was supported by the Deutsche Forschungsgemeinschaft, grants Wi 1376/1-4 & -5.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Janz, C., Wiesmüller, L. Wild-type p53 inhibits replication-associated homologous recombination. Oncogene 21, 5929–5933 (2002). https://doi.org/10.1038/sj.onc.1205757
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205757
Keywords
This article is cited by
-
Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation
BMC Pulmonary Medicine (2021)
-
Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity
Oncogene (2016)
-
The role of DNA damage responses in p53 biology
Archives of Toxicology (2015)
-
Chromosome instability and deregulated proliferation: an unavoidable duo
Cellular and Molecular Life Sciences (2012)
-
Suppression of replication fork progression in low-dose-specific p53-dependent S-phase DNA damage checkpoint
Oncogene (2006)